Eric Eldering

Positions and Employment SHORT CV Postdoctoral training Masters and Doctorate 1987 Masters degree Molecular Biology/Biochemistry University of Amsterdam 1987-1992 PhD training at the Central Laboratory of the Netherlands Red Cross Bloodtransfusion Service, Dept. Autoimmune diseases, under supervision of dr. C. E. Hack 1992 Ph.D. thesis: “Structure Function studies on the serpin C1 inhibitor". ( promotor Prof R.J. Aalberse, co-promotor dr C.E.Hack, Univ. of Amsterdam) Professional work experience 1992-1994 Postdoctoral studies at the Institut Pasteur in Paris at the Dept of Immunogénétique under the supervision of Dr Mario Tosi. Funded by EMBO and Inserm scholarships. 1994-1997 Postdoctoral studies at the the Central Laboratory of the Netherlands Red Cross Bloodtransfusion Service, Dept. Autoimmune diseases, funded by NWO (Dutch Organistion for Scientific Research) 1997-2002 Postdoctoral studies at the Academic Medical Centre funded by the Dutch Heart foundation & Dutch Cancer foundation, Depts. of Biochemistry and Experimental Immunology 2002-2007 Tenure position at the Academic Medical Centre, Dept of Experimental Immunology 2008-2012 Associate professor and Deputy head at the Dept of Experimental Immunology 2012-present Professor of Molecular Immuno-Hematology Brief outline of research activities Apoptosis, or programmed cell death, is of crucial importance in the immune system and in cancer. The group of Eric Eldering at the Dept of Experimental Immunology has studied apoptosis regulation in normal and pathological immune cells since 2002. We have expanded these research lines to include wider fundamental and translational aspects in Immuno-Hematology. We study human and (genetically modified) murine tissues in two themes of research. THEME 1. Hemato-oncological work on Chronic Lymphocytic Leukemia (CLL), in close collaboration with hematologist professor Arnon Kater. We study three interrelated areas: a) CLL genetics and molecular diagnostics b) The leukemic microenvironment and novel drugs c) Interaction between the immune system and CLL THEME 2 Shaping the immune response. We have demonstrated that upon antigen triggering, Bcl-2 members Noxa and Mcl-1 control outgrowth of high affinity lymphocytes as well as clonal diversity. We uncovered a novel role for Noxa in Darwininan selection of the fittest antigen-responsive clones from the naive lymphocyte pool. Currently our research has shifted towards Immunometabolism; we focus on the intrinsic metabolic changes in CLL as well as the impact of malignant cells on (CAR) T cell function and metabolism.